The Health Pulse S3E10: Are Genomics the Key to Placebo-Free Clinical Trials?
Nino da Silva, Deputy Director at BC Platforms, shares his view on trends in drug development and clinical research, including the integration of genetic data into drug development with synthetic control arms, the importance of data protection and the growth of Asia as a critical R&D hub.
Are placebo-free clinical trials the next normal? Nino da Silva thinks so. In this episode, he shares his views on trends in drug development and clinical research, including the integration of genetic data into drug development with synthetic control arms and the importance of data protection.
Da Silva is an international leader in medical informatics, health care and business strategy. He is currently Deputy Managing Director at BC Platforms, a Singapore-based global data science solutions leader in personalized health, drug discovery and life sciences research.
Guest host Antonio De Castro talks with da Silva about advancements in drug discovery and development by combining genetic data with phenotypic data. For example, synthetic control arms incorporate external health data into clinical trials to speed up drug development, reduce trial costs and address ethical concerns. Improved access to data from many research fields and the real world make the adoption of synthetic control arms possible. Da Silva explains the importance of trusted research environments (TRE) and trusted collaboration environments (TCE) in enabling highly dynamic research with analytics, while protecting citizens’ data privacy. Also critical to this work is the ability to harmonize and make comparable data from multiple sources and geographies. Da Silva leaves us with his thoughts on the importance of diversity and representation in clinical trials and the role of the Asia Pacific region as a growing R&D hub for life sciences.
All presentations represent the opinions of the presenter and do not represent the position or the opinion of SAS.
Da Silva is an international leader in medical informatics, health care and business strategy. He is currently Deputy Managing Director at BC Platforms, a Singapore-based global data science solutions leader in personalized health, drug discovery and life sciences research.
Guest host Antonio De Castro talks with da Silva about advancements in drug discovery and development by combining genetic data with phenotypic data. For example, synthetic control arms incorporate external health data into clinical trials to speed up drug development, reduce trial costs and address ethical concerns. Improved access to data from many research fields and the real world make the adoption of synthetic control arms possible. Da Silva explains the importance of trusted research environments (TRE) and trusted collaboration environments (TCE) in enabling highly dynamic research with analytics, while protecting citizens’ data privacy. Also critical to this work is the ability to harmonize and make comparable data from multiple sources and geographies. Da Silva leaves us with his thoughts on the importance of diversity and representation in clinical trials and the role of the Asia Pacific region as a growing R&D hub for life sciences.
All presentations represent the opinions of the presenter and do not represent the position or the opinion of SAS.
